UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
January 30, 2015
Commission File Number: 001-35990
Prosensa Holding N.V.
J.H. Oortweg 21
2333 CH Leiden
The Netherlands
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨
Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨
Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrants home country), or under the rules of the home country exchange on which the registrants securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrants security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.
INCORPORATION BY REFERENCE
This report on Form 6-K shall be deemed to be incorporated by reference into the registration statements on Form F-3 (Registration Number 333-197240) and Form S-8 (Registration Number 333-194650) of Prosensa Holding N.V. (the Registrant) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.
On January 30, 2015, BioMarin Pharmaceutical Inc. (BioMarin) announced the completion of the subsequent offering period and final results for its previously-announced tender offer by subsidiaries of BioMarin to purchase all of the issued and outstanding ordinary shares, nominal value 0.01 per share, of the Registrant (the Shares).
On the same day, the Registrant issued a press release announcing its intention to (1) voluntarily delist the Shares from the NASDAQ Global Select Market and (2) upon satisfaction of the applicable requirements, deregister the Shares under the Securities Exchange Act of 1934, as amended (the Exchange Act) and to suspend its reporting obligations under the Exchange Act once it is eligible to do so, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
List of Exhibits
Exhibit 99.1 | Press release issued by Prosensa Holding N.V., dated January 30, 2015. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
PROSENSA HOLDING N.V. | ||
By: | /s/ Giles Campion | |
Name: Giles Campion | ||
Title: Managing Director | ||
By: | /s/ Scott Clarke | |
Name: Scott Clarke | ||
Title: Managing Director |
Dated: January 30, 2015
EXHIBIT INDEX
No. |
Description | |
99.1 | Press release issued by Prosensa Holding N.V., dated January 30, 2015. |
Exhibit 99.1
Contacts: | ||
Investors | Media | |
Traci McCarty | Debra Charlesworth | |
BioMarin Pharmaceutical Inc. | BioMarin Pharmaceutical Inc. | |
(415) 455-7558 | (415) 455-7451 |
January 30, 2015
For Immediate Release
Prosensa Announces Intent to Voluntarily Delist from NASDAQ
Leiden, The Netherlands, Jan. 30, 2015 Prosensa Holding N.V. (NASDAQ: RNA) (Prosensa or the Company), the biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, announced today that it intends to voluntarily delist the registered shares of the Company, nominal value 0.01 per share (the Shares), from the NASDAQ Global Select Market (NASDAQ). Upon satisfaction of the applicable requirements for deregistration, Prosensa also intends to deregister the Shares under the Securities Exchange Act of 1934, as amended (the Exchange Act) and to suspend its reporting obligations under the Exchange Act once it is eligible to do so.
As previously disclosed, BioMarin Falcons B.V. and BioMarin Giants B.V., both indirect or direct subsidiaries of BioMarin Pharmaceutical Inc. (together, Purchaser), commenced a tender offer for all of Prosensas outstanding Shares at a purchase price of $17.75 per Share, net to the seller in cash (the Cash Consideration), plus one non-transferrable contingent value right (CVR) per Share, which represents the contractual right to receive cash payments of up to $4.14 per Share in the aggregate upon the achievement of certain product approval milestones, without interest thereon and less any applicable withholding taxes (the Offer). The subsequent offering period for the Offer expired at 6:00 p.m., New York City time, on January 29, 2015, and Purchaser has accepted for payment and paid for all Shares validly tendered pursuant to the Offer (including during the subsequent offering period), constituting approximately 96.76% of Prosensas outstanding Shares.
Now that the Offer has closed, BioMarin and Purchaser intend to complete a corporate reorganization of Prosensa and its subsidiaries through a sale of all of Prosensas assets to, and assumption of all of Prosensas liabilities by, BioMarin Falcons or its designee (the Asset Sale), followed by the dissolution and liquidation of Prosensa. In conjunction with the Asset Sale, Prosensa will issue an advanced liquidation distribution to its remaining shareholders with each remaining shareholder receiving a cash payment equal to the Cash Consideration per Share as well as one CVR per Share, without interest thereon and less any applicable withholding taxes. If a shareholder of Prosensa holds its shares of Prosensa through the Depositary Trust Company, the shareholder will receive its advanced liquidation distribution through the Depositary Trust Company. Following the Asset Sale and advanced liquidation distribution, Prosensa is not expected to have any assets and no further distributions are expected to be made.
In light of the fact that the Offer has closed and that Purchaser intends, as described above, to complete the acquisition by effecting the Asset Sale, as well as certain other factors, Prosensa has determined to cause the listing of the Shares to be withdrawn from NASDAQ. In accordance with this decision, the Company notified NASDAQ of its intent to remove its Shares from listing on NASDAQ and its intent to file a Form 25, Notification of Removal from Listing and/or Registration under Section 12(b) of the Exchange Act (Form 25), with the SEC to delist and/or deregister the Shares. We anticipate trading of the Shares on NASDAQ will be suspended shortly after the filing of the Form 25.
Upon satisfaction of the applicable requirements for deregistration, Prosensa also intends to file a Form 15 with the SEC under the Exchange Act, requesting the deregistration of the Shares under the Exchange Act and the suspension of the Companys reporting obligations under the Exchange Act.
The Company reserves the right, for any reason, to delay these filings or to withdraw them prior to their effectiveness, and to otherwise change its plans in this regard.
About Prosensa Holding N.V.
Prosensa is a biotechnology company engaged in the discovery and development of RNA-modulating therapeutics for the treatment of genetic disorders. Its primary focus is on rare neuromuscular and neurodegenerative disorders with a large unmet medical need, including Duchenne muscular dystrophy, Myotonic Dystrophy and Huntingtons disease.
Prosensas current portfolio includes six compounds for the treatment of DMD, all of which have received orphan drug status in the United States and the European Union. The compounds use an innovative technique called exon-skipping to provide a personalized medicine approach to treat different populations of DMD patients. www.prosensa.com
Safe Harbor Statement
Some of the statements contained in this announcement are forward-looking statements, including statements regarding the expected consummation of the Asset Sale and advanced liquidation distribution, which involves a number of risks and uncertainties, the possibility that the transaction will not be completed and other risks and uncertainties discussed in Prosensas public filings with the SEC, including the risk factors sections of Prosensas annual report on Form 20-F for the year ended December 31, 2013, as well as the tender offer documents filed by BioMarin and the solicitation/recommendation statement filed by Prosensa. These statements are based on current expectations, assumptions, estimates and projections, and involve known and unknown risks, uncertainties and other factors that may cause results, levels of activity, performance or achievements to be materially different from any future statements. these statements are generally identified by words or phrases such as believe, anticipate, expect, intend, plan, will, may, should, estimate, predict, potential, continue or the negative of such terms or other similar expressions. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results and the timing of events may differ materially from the results and/or timing discussed in the forward-looking statements, and you should not place undue reliance on these statements. BioMarin and Prosensa disclaim any intent or obligation to update any forward-looking statements as a result of developments occurring after the period covered by this report or otherwise.
`/\`;<0%?M]IG?';?PE+C.B(-!*](8_J7CRI MK8`=N#/!*=KH!^`E8_\`&/_:``P#`0`"$`,0```0"KX3FK0N*$'<^@>9-VE/ M%`"2Q?+\F?&\GNU!:Q@9_P#TE3.E`Z"5]+S_`$````#80```````#FT````` M``#_Q``F$`$``@("`@(!!0$!```````!$2$`,4%188%QD:$00+'!\?`P_]H` M"`$!``$_$,5!9.M\?&0[_P",.S5?6*P8+00O\&0R/LQ' M8`^6(^,2*(<@"/3'G8K!RJ4^L0WV9D88W\@2N2*1J0P@'021$Y`%D.GB;,!W MDAZ_&)"6#C!"FCUK/)17UD.]?H1%((J#M`O/C'O=*?VX`I1YQ'8"N3*BF1E@ M;6B6@U@X@9"%2`1VQ>R5'SD?75047%02VK&1(!9!Z$H0B9FLKHF'A8A,-KE1 MQ8@@$MS/[9$'FUD[-3G(;H@1\!7N),;P("A`(C54#G&C*5`HBY+*,25A2N\0 M@@*6(!.%R$)CJPA1$S,TB-N?6]4U#BR,4+99S20K)&^9FFA;A8@B6\`"4('P MZ_0,^)1Q"%,W_&!!_*%NU*`!%7W!%];TC!X&=2>I@&:5)FL3M;JKM=0XIPZX M:V/N,J^>P=#"^CBMR"7;8"^<#$ED$RLD">$&+K"R(C ,-`#X`U@L16#)6@`]7DZ,W>VFE3O%@"D*%T055PC!YIF&M[ MB./6`EC1=9Z$!]9#A*5YGEJ:Q$G<41`:P38?#Q@0$:[K60B;(>*U_P"8)YG< M#@#+)A#&&8F!,`Z01[P']-$!K6``'7]?L2O$>LT]?C-!X_&%!Q^/V(#_Q``G M$`$``@("`@`&`P$!```````!`!$A,4%187&!D:&QT?`00.'!,/_:``@!`P`! M/Q""=&I2<:@BH;V.I85*V/4<6T=S*&2Z(7]'VB&UHA4"]`_!*@^'!]TFY8!* M7U0F,W7<=/!J`K+19?8XANN2!FFPNO!$KG`3%=XNK]2Z+X_C2&51ABL_Y%P: MM;W*<)QV-GJO$S@K2O4''$BW.?&*F9<@'Q?M*+G@L$;&FJK44@_&@X^/B;_5 MHI?O<-$IP;_QUTP`JAS=_P",UL5'XZF.:JG[\8EOE'$:!W6ZUQICK<<7 ]5B(H6-'YQ*?ST"`=!%>WN,K;2\A=\T#429N<5W03K$6OUD`PK M]J=2$*INFKK=?35R\&!E*=G#6I7DZG!;0 (;BABO)50NE[',%%5Z?"XG"]3U^D2M:(%#'JNIGSD_?I4[G MU<=R'@];X8-S#C?X)5]PP[\8A``/=7I$``)[JG'H7B;$)E15;LEAA.B@GSR^ MDJ*VW=/='+P2Y"N*,?.XUQ>WLO[9FP*=SQL>)6*X.(ZK@T>I;WJ"FFH=,04T MU%>]0S1V7P'F%X9#C>:N!1$ )=>(%8U7]%LJ]3?PFAXCO^B`_\0`)Q`! M``("`0,$`@(#`````````0`1(3%!46%Q@9&AP;'P$$`PX?'_V@`(`0(``3\0 M@G1J:QTB*WX2U+5$&=02T&>D3:/(&:\32%.L-6O+DFHY4>A^SA);><]CI12( MR;R>[$&RE]%4G:+`OB8.1*3%5.>HXG(9./XLB5#",<9_U+3TH1W,? D`@ /KI,EP?O2.:8!GQ Q7\ M4&-,WCQ$,JX4HXW5Q@N@4^I3%)8-A"NQSS\2[ZLM>**QXA6C8"%:X',H8;A- M=?6M>D9L"KRIAN#6-`8@PEH^Y2B;@*S5-S!]QM_34,SK'=A'8*,YE09LMTU8 M,'Q+,=!2E<]&`")'(VTZXP115!O6NQ PZ-GO1+EC1MI5UQGK*D!*JT M()CXX[]I8#IL-8>_G^*(Y02!2E;XF9U7R2TWA'/'2&XP&XZP(..FO#'5:;S" MT4R))KAP?B.&+E4\6`5'0W#W"@%W&W17YRID2@(8%68XX@@50BHNC]PX%!B> ME<=HS%74T`.V>TK["\>E:_$`LH88<6;UXE"FTQ^^*B#@<0%O'#YZQOC.C^!J M'I>T71KFEO>;V"C."T.(6WP%'&%HENL:W`C5!8+R)J=B53YU"#=4+%_$15(N M"G%!4,*S*Z`"EEV>>Y`^/@;V#$`1F@VEIS$O#Q'5<'$!JPZ34-0CA]B/ M?B,"AUR\2]@P0FGP&XH535C#T(H1W;%^2DUTO,K8>P7R`,5T@4YH!K'NQ(:? M$!]<5`.`.3#YE"L364$5?Y_X\2HZ_P#2*4SWG',&D[(:70_HA>4P#EOTCWVF &NU?T?__9 ` end